These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10224386)

  • 1. Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy.
    Vrtala S; Hirtenlehner K; Susani M; Hufnagl P; Binder BR; Vangelista L; Pastore A; Sperr WR; Valent P; Ebner C; Kraft D; Valenta R
    Int Arch Allergy Immunol; 1999; 118(2-4):218-9. PubMed ID: 10224386
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivatives.
    Pauli G; Purohit A; Oster JP; de Blay F; Vrtala S; Niederberger V; Kraft D; Valenta R
    Int Arch Allergy Immunol; 1999; 118(2-4):216-7. PubMed ID: 10224385
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
    Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
    Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy.
    Ferreira F; Hirtenlehner K; Jilek A; Godnik-Cvar J; Breiteneder H; Grimm R; Hoffmann-Sommergruber K; Scheiner O; Kraft D; Breitenbach M; Rheinberger HJ; Ebner C
    J Exp Med; 1996 Feb; 183(2):599-609. PubMed ID: 8627171
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Aglas L; Bethanis A; Chrusciel P; Stolz F; Gruen M; Jaakkola UM; Jongejan L; Yatkin E; Van Ree R
    Front Immunol; 2020; 11():2118. PubMed ID: 33013894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
    Wiedermann U; Herz U; Baier K; Vrtala S; Neuhaus-Steinmetz U; Bohle B; Dekan G; Renz H; Ebner C; Valenta R; Kraft D
    Int Arch Allergy Immunol; 2001 Sep; 126(1):68-77. PubMed ID: 11641608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
    Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
    J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
    Mahler V; Vrtala S; Kuss O; Diepgen TL; Suck R; Cromwell O; Fiebig H; Hartl A; Thalhamer J; Schuler G; Kraft D; Valenta R
    Clin Exp Allergy; 2004 Jan; 34(1):115-22. PubMed ID: 14720271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1.
    Vrtala S; Hirtenlehner K; Susani M; Akdis M; Kussebi F; Akdis CA; Blaser K; Hufnagl P; Binder BR; Politou A; Pastore A; Vangelista L; Sperr WR; Semper H; Valent P; Ebner C; Kraft D; Valenta R
    FASEB J; 2001 Sep; 15(11):2045-7. PubMed ID: 11511511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.
    Shirasaki H; Yamamoto T; Koyanagi Y; Watanabe N; Himi T
    Allergol Int; 2008 Mar; 57(1):93-6. PubMed ID: 18209509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspective of purified natural and recombinant allergens in diagnosis and treatment of inhalant allergies.
    van Ree R; van Leeuwen A; Bond J; Aalberse R
    Int Arch Allergy Immunol; 1999; 118(2-4):212-3. PubMed ID: 10224383
    [No Abstract]   [Full Text] [Related]  

  • 12. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
    van Hage-Hamsten M; Kronqvist M; Zetterström O; Johansson E; Niederberger V; Vrtala S; Grönlund H; Grönneberg R; Valenta R
    J Allergy Clin Immunol; 1999 Nov; 104(5):969-77. PubMed ID: 10550741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of recombinant allergens for diagnosis and therapy of IgE-mediated allergies.
    Kraft D; Ferreira F; Vrtala S; Breiteneder H; Ebner C; Valenta R; Susani M; Breitenbach M; Scheiner O
    Int Arch Allergy Immunol; 1999; 118(2-4):171-6. PubMed ID: 10224369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of mutants of a highly cross-reactive calcium-binding protein from Brassica pollen for allergen-specific immunotherapy.
    Garmatiuk T; Swoboda I; Twardosz-Kropfmüller A; Dall'Antonia F; Keller W; Singh MB; Bhalla PL; Okada T; Toriyama K; Weber M; Ghannadan M; Sperr WR; Blatt K; Valent P; Klein B; Niederberger V; Curin M; Balic N; Spitzauer S; Valenta R
    Immunobiology; 2013 Sep; 218(9):1155-1165. PubMed ID: 23790497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral immune responses to recombinant tree pollen allergens (Bet v I and Bet v II) in mice: construction of a live oral allergy vaccine.
    Vrtala S; Grote M; Ferreira F; Susani M; Stocker B; Kraft D; Valenta R
    Int Arch Allergy Immunol; 1995; 107(1-3):290-4. PubMed ID: 7613152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population.
    Pauli G; Purohit A; Oster JP; De Blay F; Vrtala S; Niederberger V; Kraft D; Valenta R
    Clin Exp Allergy; 2000 Aug; 30(8):1076-84. PubMed ID: 10931114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2.
    Vrtala S; Mayer P; Ferreira F; Susani M; Sehon AH; Kraft D; Valenta R
    J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):913-21. PubMed ID: 8939154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen.
    Menz G; Dolecek C; Schönheit-Kenn U; Ferreira F; Moser M; Schneider T; Suter M; Boltz-Nitulescu G; Ebner C; Kraft D; Valenta R
    Clin Exp Allergy; 1996 Jan; 26(1):50-60. PubMed ID: 8789543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of specific IgE antibodies in the sera of patients allergic to birch pollen using recombinant allergens Bet v 1, Bet v 2, Bet v 4: evaluation of different IgE reactivity profiles.
    Rossi RE; Monasterolo G; Monasterolo S
    Allergy; 2003 Sep; 58(9):929-32. PubMed ID: 12911423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients.
    Nopp A; Halldén G; Lundahl J; Johansson E; Vrtala S; Valenta R; Grönneberg R; Van Hage-Hamsten M
    J Allergy Clin Immunol; 2000 Jul; 106(1 Pt 1):101-9. PubMed ID: 10887312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.